Takeda Pharmaceutical received a complete response letter from the FDA regarding alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone in type 2 diabetes.
Read more
Takeda’s Type 2 Diabetes Therapies Set Back Again by FDA
Posted in Drugs